Electronic Aspirin Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Electronic Aspirin Market is Segmented By Pain Type (Migraines Cluster Headaches, Head and Facial Pain), By End-User (Hospitals, Clinics, Ambulatory Surgical Centers), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Electronic Aspirin Market Overview

[180 pages] Report analyses the Global Electronic aspirin Market shares, recent trends, and market player analysis. North America region holds the largest market share of the global electronic aspirin market. The Competitive rivalry intensifies with Autonomic Technologies, Inc etc.

Electronic aspirin is a novel medical technology that aims to reduce pain in conditions such as migraines, cluster headaches and other head and facial pain. Electronic aspirin relieves pain through nerve stimulated implantable device and is used to block the Sphenopalatine Ganglion Signals (SPG), a group of nerve cells associated with the trigeminal nerve and is characterized with the identification of headache disorders in humans.

Electronic Aspirin Market Summary

For More Insights Download Sample

Electronic Aspirin Market Dynamics

The increasing number of tobacco consumers, increasing prevalence of migraine and technological advancements in this segment is expected to drive the electronic aspirin market during the forecast period. Also, government funding and favourable reimbursement facilities for the development of innovative devices.

The increasing prevalence of headaches and migraine is expected to drive the global electronic aspirin market growth

As per the journal on Headache and Pain, published by the American Association for the Advancement of Science (AAAS), smoking more than five cigarettes a day triggers headaches effectively.

According to the World Health Organization (WHO) 2016, globally, it has been estimated that prevalence among adults of current headache disorder (symptomatic at least once within the last year) is about 50%. Half to three-quarters of adults aged 18–65 years in the world have had a headache in the last year and, among those individuals, 30% or more have reported migraine. As per the Migraine Research Foundation (MRF), migraine is the third most prevalent disease, and about 1 billion people suffer from the same globally. Moreover, more than 4 million people experience chronic daily migraines – with at least 15 migraine days per month.

A few of the side effects associated with electronic aspirin is likely to hamper the market growth

There is no major threatening risk attached to the use of electronic aspirin; some of the reported symptoms include lower blood pressure, throat numbness, or nausea. However, in rare cases, the symptoms can be a nasal infection, nasal bleeding and a slight increase in headache.

COVID-19 Impact on Electronic Aspirin Market

The novel COVID-19 pandemic has affected the development of an array of industrial areas, the technology sector, food & beverage industry, healthcare, and other sectors, is no doubt. The coronavirus (COVID-19 outbreak and lockdowns in various countries worldwide has impacted businesses' economic status in all sectors. Private healthcare is one such sector, which has been impacted significantly by the COVID-19 pandemic. Moreover, the coronavirus pandemic has hampered the development, production, supply, and other healthcare products and affected various healthcare businesses' growth.

As a result, the impact of the COVID-19 pandemic is also expected to decrease the growth of the market.

Electronic Aspirin Market Segment Analysis

The Migraines, Cluster Headaches segment is expected to hold the largest share in this market segment

The headache’s segment is expected to hold the largest market share due to the growing prevalence of headaches worldwide. According to the World Health Organization, 50% of the global population suffer from headache. As per the Migraine Research Foundation (MRF), migraine is the third most prevalent disease, and about 1 billion people suffer from the same globally. Moreover, more than 4 million people experience chronic daily migraines – with at least 15 migraine days per month. CH is relatively uncommon, affecting fewer than 1 in 1000 adults, affecting six men to each woman.

The hospital's segment is expected to hold the largest share in this market segment

The hospital segment is expected to dominate the market growth. This is mainly owing to the increasing number of patients suffering from conditions that are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals and adequate reimbursement policies are also contributing to the growth of this segment. Increasing cases of headache disorder and a rising number of people opting for its treatment in hospitals are predicted to boost the market growth.

Global Electronic Aspirin Market Geographical Share

North America region holds the largest market share of the global electronic aspirin market

North America is expected to hold a major market share in the global electronic aspirin market due to changing lifestyles among people and the increasing prevalence rate of neurological disorders. Headaches and migraines are among the most common disorders of the human nervous system worldwide. In the United States, over 15 per cent of all adults complain about severe headaches or migraines, with prevalence among women more than twice as high as among men. In addition, the prevalence of headaches among U.S. adults is distinctly higher among younger people than among those aged 65 years and older. A Statista survey from 2017 found that 18 per cent of respondents suffered multiple times a month from headaches.

Electronic Aspirin Market Companies

The global electronic aspirin market is sightly competitive with the presence of global companies. Some of the key players which are contributing to the growth of the market include Currently, Autonomic Technologies, Inc. is the sole company investigating the future of electronic aspirin.

Autonomic Technologies, Inc

Overview: Autonomic Technologies, Inc is a medical device company headquartered in the San Francisco Bay Area with an office in Germany focused on developing and commercialization of innovative therapies for the treatment of autonomic disorders, particularly severe headaches. ATI is backed by world-class European and US investors, including Edmond de Rothschild Investment Partners, Forbion Capital Partners, HBM Healthcare Investments, Kleiner Perkins Caufield and Byers, InterWest Partners, Aberdare Ventures, Novartis Venture Funds, Capital Royalty Group and Cleveland Clinic.

Product Portfolio: The Company offers a miniaturized implantable neurostimulation device to provide rapid relief from the debilitating pain and suffering caused by severe headaches.

Key Developments: In March 2017, ATI received an expanded indication (CE mark) in Europe for the Pulsante SPG Microstimulator system to include pain relief for highly affected migraine patients. The Pulsante Microstimulator System provides on-demand stimulation of the SPG, which is known for cluster headache and migraine. It is the first implantable neurostimulation therapy to receive a CE mark for headache and migraine-related pain relief.